Isolation and characterization of anti ROR1 single chain fragment variable antibodies using phage display technique

Human Antibodies

Volumn 25, Issue 1-2, 2017, Pages 57-63

  Aghebati Maleki, Leili ^a,b   Younesi, Vahid ^c,d   Jadidi Niaragh, Farhad ^a,b   Baradaran, Behzad ^a   Majidi, Jafar ^a   Yousefi, Mehdi ^a,b  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ALBORZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d Pishtaz Teb Medical Co   (Iran)

Author keywords

Phage display technique; Receptor tyrosine kinases; ROR1; ScFv

Indexed keywords

PROTEIN TYROSINE KINASE; RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY; PEPTIDE LIBRARY; PROTEIN BINDING; RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR; RECOMBINANT PROTEIN; ROR1 PROTEIN, HUMAN;

ARTICLE; BINDING AFFINITY; BIOPANNING; CHEMOLUMINESCENCE; CLONING; COLONY FORMING UNIT; DNA SEQUENCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FUNCTIONAL ASSESSMENT; MONOCLONAL PHAGE ENZYME LINKED IMMUNOSORBENT ASSAY; PHAGE DISPLAY; POLYCLONAL PHAGE ENZYME LINKED IMMUNOSORBENT ASSAY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SCREENING; WESTERN BLOTTING; ANTIBODY SPECIFICITY; CELL SURFACE DISPLAY; CHEMISTRY; ESCHERICHIA COLI; GENE EXPRESSION; GENETICS; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; MOLECULAR CLONING; PEPTIDE LIBRARY; PROTEIN DOMAIN;

ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; CELL SURFACE DISPLAY TECHNIQUES; CLONING, MOLECULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; GENE EXPRESSION; HUMANS; PEPTIDE LIBRARY; PROTEIN BINDING; PROTEIN DOMAINS; RECEPTOR TYROSINE KINASE-LIKE ORPHAN RECEPTORS; RECOMBINANT PROTEINS; SINGLE-CHAIN ANTIBODIES;

EID: 85014105602     PISSN: 10932607     EISSN: 1875869X     Source Type: Journal    
DOI: 10.3233/HAB-170310     Document Type: Article

References (20)

1. N.B. Fernandez, D. Lorenzo, M.E. Picco, G. Barbero, L.S. Dergan-Dylon et al., ROR1 contributes to melanoma cell growth and migration by regulating N-cadherin expression via the PI3K/Akt pathway, Mol Carcinog 55(11) (2016 Nov), 1772-1785.
2. M. Hojjat-Farsangi, F. Ghaemimanesh, A.H. Daneshmanesh, A.A. Bayat, J. Mahmoudian et al., Inhibition of the receptor tyrosine kinase ROR1 by anti-ROR1 monoclonal antibodies and siRNA induced apoptosis of melanoma cells, PLoS One 8(4) (2013), e61167.
3. M. Hojjat-Farsangi, A. Moshfegh, A.H. Daneshmanesh et al., The receptor tyrosine kinase ROR1-an oncofetal antigen for targeted cancer therapy, Semin Cancer Biol 29 (2014 Dec), 21-31.
4. N. Borcherding, D. Kusner, G.H. Liu and W. Zhang, ROR1, an embryonic protein with an emerging role in cancer biology, Protein Cell 5(7) (2014 Jul), 496-502.
5. M. Shabani, J. Naseri and F. Shokri, Receptor tyrosine kinaselike orphan receptor 1: a novel target for cancer immunotherapy, Expert Opin Ther Targets 19(7) (2015 Jul), 941-955.
6. H. Dave, M.R. Anver, D.O. Butcher, P. Brown, J. Khan, A.S. Wayne, S. Baskar and C. Rader, Restricted cell surface expression of receptor tyrosine kinase ROR1 in pediatric B-lineage acute lymphoblastic leukemia suggests targetability with therapeutic monoclonal antibodies, PLoS One 7(12) (2012), e52655.
7. S. Zhang, L. Chen, J. Wang-Rodriguez, L. Zhang, B. Cui, W. Frankel, R. Wu and T.J. Kipps, The onco-embryonic antigen ROR1 is expressed by a variety of human cancers, Am J Pathol. 181(6) (2012 Dec), 1903-1910.
8. A.H. Daneshmanesh, A. Porwit, M. Hojjat-Farsangi, M. Jeddi-Tehrani, K.P. Tamm et al., Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies, Leuk Lymphoma 54 (2013), 843-850.
9. J. Yang, S. Baskar, K.Y. Kwong, M.G. Kennedy, A. Wiestner and C. Rader, Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies, PLoS One 6(6) (2011), e21018.
10. S. Baskar, A. Wiestner, W.H. Wilson, I. Pastan and C. Rader, Targeting malignant B cells with an immunotoxin against ROR1, MAbs 4(3) (2012 May-Jun), 349-361.
11. M.P. O'Connell, K. Marchbank, M.R. Webster, A.A. Valiga, A. Kaur et al., Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2, Cancer Discov 3 (2013), 1378-1393.
12. L.A. Maleki, B. Baradaran, J. Majidi, M. Mohammadian and F.Z. Shahneh, Future prospects of monoclonal antibodies as magic bullets in immunotherapy, Hum Antibodies 22(1-2) (2013), 9-13.
13. M. Motallebnezhad, V. Younesi and L. Aghebati-Maleki, Antiproliferative and apoptotic effects of a specific anti-insulinlike growth factor I receptor single chain antibody on breast cancer cells, Tumour Biol. 2016 Sep 17.
14. L.A. Maleki, J. Majidi, B. Baradaran, J. Abdolalizadeh and A.M. Akbari, Production and characterization of murine monoclonal antibody against synthetic peptide of CD34, Hum Antibodies 22(1-2) (2013), 1-8.
15. L. Aghebati Maleki, J. Majidi, B. Baradaran, A. Movassaghpour and J. Abdolalizadeh, Generation and Characterization of Anti-CD34 Monoclonal Antibodies that React with Hematopoietic Stem Cells, Cell J 16(3) (2014 Fall), 361-366.
16. P. Carter, Improving the efficacy of antibody-based cancer therapies, Nature Reviews Cancer 1(2) (2001), 118-129.
17. L. Aghebati-Maleki, B. Bakhshinejad and B. Baradaran, Phage display as a promising approach for vaccine development, Journal of Biomedical Science 23(1) (2016 Sep 29), 66.
18. C.M. Hammers and J.R. Stanley, Antibody phage display: technique and applications, J Invest Dermatol 134(2) (2014 Feb), e17.
19. J. Bazan, I. Ca?kosinski and A. Gamian, Phage display-a powerful technique for immunotherapy: 1. Introduction and potential of therapeutic applications, Hum Vaccin Immunother 8(12) (2012 Dec 1), 1817-1828.
20. H. Nickho, V. Younesi, L. Aghebati-Maleki, M. Motallebnezhad, J. MajidiZolbanin, A. Movassagh Pour and M. Yousefi, Developing and Characterization of Single Chain Variable Fragment (scFv) Antibody Against Frizzled 7 (Fzd7) Receptor. Bioengineered, 2016 Nov.